Vericel (VCEL) Net Income towards Common Stockholders (2010 - 2026)
Vericel (VCEL) posted Net Income towards Common Stockholders of $1.8 million for Q2 2026, up 125.78% sequentially from -$6.8 million in Q1 2026, and up 276.83% YoY from $467849.6 in Q2 2025.
Powered by 
Analysis
Vericel (VCEL) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Vericel has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $1.8 million in Q2 2026.
- Quarterly Net Income towards Common Stockholders rose 276.83% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.8 million (up 271.21% YoY) and the FY2025 annual result came in at $16.5 million, up 59.41% from the prior year.
- Net Income towards Common Stockholders climbed to $1.8 million in Q2 2026 per VCEL's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $23.3 million in Q4 2025 and troughed at -$164.4 million in Q2 2023.
- A 5-year average of -$8.9 million and a median of -$4.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders slumped 1734.33% in 2023, then jumped 614.21% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at $5.9 million in 2022, then surged by 119.4% to $13.0 million in 2023, then soared by 52.44% to $19.8 million in 2024, then rose by 17.47% to $23.3 million in 2025, then sank by 92.42% to $1.8 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $1.8 million, -$6.8 million, and $23.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 2.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.23 Mn |
| Mar 31, 2026 | -6.37 Mn |
| Dec 31, 2025 | 24.14 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | -529,000.00 |
| Mar 31, 2025 | -11.29 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -4.67 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | -3.66 Mn |
| Jun 30, 2023 | -5.02 Mn |
| Mar 31, 2023 | -7.48 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | -4.93 Mn |